Global Peripherally Acting Anti-Obesity Drug Supply, Demand and Key Producers, 2023-2029
The global Peripherally Acting Anti-Obesity Drug market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).
This report studies the global Peripherally Acting Anti-Obesity Drug production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Peripherally Acting Anti-Obesity Drug, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Peripherally Acting Anti-Obesity Drug that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Peripherally Acting Anti-Obesity Drug total production and demand, 2018-2029, (K Units)
Global Peripherally Acting Anti-Obesity Drug total production value, 2018-2029, (USD Million)
Global Peripherally Acting Anti-Obesity Drug production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Peripherally Acting Anti-Obesity Drug consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Peripherally Acting Anti-Obesity Drug domestic production, consumption, key domestic manufacturers and share
Global Peripherally Acting Anti-Obesity Drug production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Peripherally Acting Anti-Obesity Drug production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Peripherally Acting Anti-Obesity Drug production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)
This reports profiles key players in the global Peripherally Acting Anti-Obesity Drug market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk A/S, Pfizer Inc., Boehringer Ingelheim International GmbH, KVK Tech Inc., Gelesis Holdings, Vivus LLC., Currax Pharmaceuticals LLC, GlaxoSmithKline plc and CHEPLAPHARM Arzneimittel GmbH, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Peripherally Acting Anti-Obesity Drug market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Peripherally Acting Anti-Obesity Drug Market, By Region:
1. How big is the global Peripherally Acting Anti-Obesity Drug market?
2. What is the demand of the global Peripherally Acting Anti-Obesity Drug market?
3. What is the year over year growth of the global Peripherally Acting Anti-Obesity Drug market?
4. What is the production and production value of the global Peripherally Acting Anti-Obesity Drug market?
5. Who are the key producers in the global Peripherally Acting Anti-Obesity Drug market?
6. What are the growth factors driving the market demand?
This report studies the global Peripherally Acting Anti-Obesity Drug production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Peripherally Acting Anti-Obesity Drug, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Peripherally Acting Anti-Obesity Drug that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Peripherally Acting Anti-Obesity Drug total production and demand, 2018-2029, (K Units)
Global Peripherally Acting Anti-Obesity Drug total production value, 2018-2029, (USD Million)
Global Peripherally Acting Anti-Obesity Drug production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Peripherally Acting Anti-Obesity Drug consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Peripherally Acting Anti-Obesity Drug domestic production, consumption, key domestic manufacturers and share
Global Peripherally Acting Anti-Obesity Drug production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Peripherally Acting Anti-Obesity Drug production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Peripherally Acting Anti-Obesity Drug production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)
This reports profiles key players in the global Peripherally Acting Anti-Obesity Drug market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk A/S, Pfizer Inc., Boehringer Ingelheim International GmbH, KVK Tech Inc., Gelesis Holdings, Vivus LLC., Currax Pharmaceuticals LLC, GlaxoSmithKline plc and CHEPLAPHARM Arzneimittel GmbH, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Peripherally Acting Anti-Obesity Drug market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Peripherally Acting Anti-Obesity Drug Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Prescription Drugs
- Non-prescription Drugs
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Novo Nordisk A/S
- Pfizer Inc.
- Boehringer Ingelheim International GmbH
- KVK Tech Inc.
- Gelesis Holdings
- Vivus LLC.
- Currax Pharmaceuticals LLC
- GlaxoSmithKline plc
- CHEPLAPHARM Arzneimittel GmbH
- Rhythm Pharmaceuticals
1. How big is the global Peripherally Acting Anti-Obesity Drug market?
2. What is the demand of the global Peripherally Acting Anti-Obesity Drug market?
3. What is the year over year growth of the global Peripherally Acting Anti-Obesity Drug market?
4. What is the production and production value of the global Peripherally Acting Anti-Obesity Drug market?
5. Who are the key producers in the global Peripherally Acting Anti-Obesity Drug market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Peripherally Acting Anti-Obesity Drug Introduction
1.2 World Peripherally Acting Anti-Obesity Drug Supply & Forecast
1.2.1 World Peripherally Acting Anti-Obesity Drug Production Value (2018 & 2022 & 2029)
1.2.2 World Peripherally Acting Anti-Obesity Drug Production (2018-2029)
1.2.3 World Peripherally Acting Anti-Obesity Drug Pricing Trends (2018-2029)
1.3 World Peripherally Acting Anti-Obesity Drug Production by Region (Based on Production Site)
1.3.1 World Peripherally Acting Anti-Obesity Drug Production Value by Region (2018-2029)
1.3.2 World Peripherally Acting Anti-Obesity Drug Production by Region (2018-2029)
1.3.3 World Peripherally Acting Anti-Obesity Drug Average Price by Region (2018-2029)
1.3.4 North America Peripherally Acting Anti-Obesity Drug Production (2018-2029)
1.3.5 Europe Peripherally Acting Anti-Obesity Drug Production (2018-2029)
1.3.6 China Peripherally Acting Anti-Obesity Drug Production (2018-2029)
1.3.7 Japan Peripherally Acting Anti-Obesity Drug Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Peripherally Acting Anti-Obesity Drug Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Peripherally Acting Anti-Obesity Drug Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Peripherally Acting Anti-Obesity Drug Demand (2018-2029)
2.2 World Peripherally Acting Anti-Obesity Drug Consumption by Region
2.2.1 World Peripherally Acting Anti-Obesity Drug Consumption by Region (2018-2023)
2.2.2 World Peripherally Acting Anti-Obesity Drug Consumption Forecast by Region (2024-2029)
2.3 United States Peripherally Acting Anti-Obesity Drug Consumption (2018-2029)
2.4 China Peripherally Acting Anti-Obesity Drug Consumption (2018-2029)
2.5 Europe Peripherally Acting Anti-Obesity Drug Consumption (2018-2029)
2.6 Japan Peripherally Acting Anti-Obesity Drug Consumption (2018-2029)
2.7 South Korea Peripherally Acting Anti-Obesity Drug Consumption (2018-2029)
2.8 ASEAN Peripherally Acting Anti-Obesity Drug Consumption (2018-2029)
2.9 India Peripherally Acting Anti-Obesity Drug Consumption (2018-2029)
3 WORLD PERIPHERALLY ACTING ANTI-OBESITY DRUG MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Peripherally Acting Anti-Obesity Drug Production Value by Manufacturer (2018-2023)
3.2 World Peripherally Acting Anti-Obesity Drug Production by Manufacturer (2018-2023)
3.3 World Peripherally Acting Anti-Obesity Drug Average Price by Manufacturer (2018-2023)
3.4 Peripherally Acting Anti-Obesity Drug Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Peripherally Acting Anti-Obesity Drug Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Peripherally Acting Anti-Obesity Drug in 2022
3.5.3 Global Concentration Ratios (CR8) for Peripherally Acting Anti-Obesity Drug in 2022
3.6 Peripherally Acting Anti-Obesity Drug Market: Overall Company Footprint Analysis
3.6.1 Peripherally Acting Anti-Obesity Drug Market: Region Footprint
3.6.2 Peripherally Acting Anti-Obesity Drug Market: Company Product Type Footprint
3.6.3 Peripherally Acting Anti-Obesity Drug Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Peripherally Acting Anti-Obesity Drug Production Value Comparison
4.1.1 United States VS China: Peripherally Acting Anti-Obesity Drug Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: Peripherally Acting Anti-Obesity Drug Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: Peripherally Acting Anti-Obesity Drug Production Comparison
4.2.1 United States VS China: Peripherally Acting Anti-Obesity Drug Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Peripherally Acting Anti-Obesity Drug Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: Peripherally Acting Anti-Obesity Drug Consumption Comparison
4.3.1 United States VS China: Peripherally Acting Anti-Obesity Drug Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: Peripherally Acting Anti-Obesity Drug Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based Peripherally Acting Anti-Obesity Drug Manufacturers and Market Share, 2018-2023
4.4.1 United States Based Peripherally Acting Anti-Obesity Drug Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Peripherally Acting Anti-Obesity Drug Production Value (2018-2023)
4.4.3 United States Based Manufacturers Peripherally Acting Anti-Obesity Drug Production (2018-2023)
4.5 China Based Peripherally Acting Anti-Obesity Drug Manufacturers and Market Share
4.5.1 China Based Peripherally Acting Anti-Obesity Drug Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Peripherally Acting Anti-Obesity Drug Production Value (2018-2023)
4.5.3 China Based Manufacturers Peripherally Acting Anti-Obesity Drug Production (2018-2023)
4.6 Rest of World Based Peripherally Acting Anti-Obesity Drug Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based Peripherally Acting Anti-Obesity Drug Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Peripherally Acting Anti-Obesity Drug Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers Peripherally Acting Anti-Obesity Drug Production (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Peripherally Acting Anti-Obesity Drug Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Prescription Drugs
5.2.2 Non-prescription Drugs
5.3 Market Segment by Type
5.3.1 World Peripherally Acting Anti-Obesity Drug Production by Type (2018-2029)
5.3.2 World Peripherally Acting Anti-Obesity Drug Production Value by Type (2018-2029)
5.3.3 World Peripherally Acting Anti-Obesity Drug Average Price by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Peripherally Acting Anti-Obesity Drug Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hospital Pharmacies
6.2.2 Retail Pharmacies
6.2.3 Online Pharmacies
6.3 Market Segment by Application
6.3.1 World Peripherally Acting Anti-Obesity Drug Production by Application (2018-2029)
6.3.2 World Peripherally Acting Anti-Obesity Drug Production Value by Application (2018-2029)
6.3.3 World Peripherally Acting Anti-Obesity Drug Average Price by Application (2018-2029)
7 COMPANY PROFILES
7.1 Novo Nordisk A/S
7.1.1 Novo Nordisk A/S Details
7.1.2 Novo Nordisk A/S Major Business
7.1.3 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Product and Services
7.1.4 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 Novo Nordisk A/S Recent Developments/Updates
7.1.6 Novo Nordisk A/S Competitive Strengths & Weaknesses
7.2 Pfizer Inc.
7.2.1 Pfizer Inc. Details
7.2.2 Pfizer Inc. Major Business
7.2.3 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Product and Services
7.2.4 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 Pfizer Inc. Recent Developments/Updates
7.2.6 Pfizer Inc. Competitive Strengths & Weaknesses
7.3 Boehringer Ingelheim International GmbH
7.3.1 Boehringer Ingelheim International GmbH Details
7.3.2 Boehringer Ingelheim International GmbH Major Business
7.3.3 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Product and Services
7.3.4 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 Boehringer Ingelheim International GmbH Recent Developments/Updates
7.3.6 Boehringer Ingelheim International GmbH Competitive Strengths & Weaknesses
7.4 KVK Tech Inc.
7.4.1 KVK Tech Inc. Details
7.4.2 KVK Tech Inc. Major Business
7.4.3 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Product and Services
7.4.4 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.4.5 KVK Tech Inc. Recent Developments/Updates
7.4.6 KVK Tech Inc. Competitive Strengths & Weaknesses
7.5 Gelesis Holdings
7.5.1 Gelesis Holdings Details
7.5.2 Gelesis Holdings Major Business
7.5.3 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Product and Services
7.5.4 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.5.5 Gelesis Holdings Recent Developments/Updates
7.5.6 Gelesis Holdings Competitive Strengths & Weaknesses
7.6 Vivus LLC.
7.6.1 Vivus LLC. Details
7.6.2 Vivus LLC. Major Business
7.6.3 Vivus LLC. Peripherally Acting Anti-Obesity Drug Product and Services
7.6.4 Vivus LLC. Peripherally Acting Anti-Obesity Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.6.5 Vivus LLC. Recent Developments/Updates
7.6.6 Vivus LLC. Competitive Strengths & Weaknesses
7.7 Currax Pharmaceuticals LLC
7.7.1 Currax Pharmaceuticals LLC Details
7.7.2 Currax Pharmaceuticals LLC Major Business
7.7.3 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Product and Services
7.7.4 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.7.5 Currax Pharmaceuticals LLC Recent Developments/Updates
7.7.6 Currax Pharmaceuticals LLC Competitive Strengths & Weaknesses
7.8 GlaxoSmithKline plc
7.8.1 GlaxoSmithKline plc Details
7.8.2 GlaxoSmithKline plc Major Business
7.8.3 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Product and Services
7.8.4 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.8.5 GlaxoSmithKline plc Recent Developments/Updates
7.8.6 GlaxoSmithKline plc Competitive Strengths & Weaknesses
7.9 CHEPLAPHARM Arzneimittel GmbH
7.9.1 CHEPLAPHARM Arzneimittel GmbH Details
7.9.2 CHEPLAPHARM Arzneimittel GmbH Major Business
7.9.3 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Product and Services
7.9.4 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.9.5 CHEPLAPHARM Arzneimittel GmbH Recent Developments/Updates
7.9.6 CHEPLAPHARM Arzneimittel GmbH Competitive Strengths & Weaknesses
7.10 Rhythm Pharmaceuticals
7.10.1 Rhythm Pharmaceuticals Details
7.10.2 Rhythm Pharmaceuticals Major Business
7.10.3 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Product and Services
7.10.4 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.10.5 Rhythm Pharmaceuticals Recent Developments/Updates
7.10.6 Rhythm Pharmaceuticals Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Peripherally Acting Anti-Obesity Drug Industry Chain
8.2 Peripherally Acting Anti-Obesity Drug Upstream Analysis
8.2.1 Peripherally Acting Anti-Obesity Drug Core Raw Materials
8.2.2 Main Manufacturers of Peripherally Acting Anti-Obesity Drug Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Peripherally Acting Anti-Obesity Drug Production Mode
8.6 Peripherally Acting Anti-Obesity Drug Procurement Model
8.7 Peripherally Acting Anti-Obesity Drug Industry Sales Model and Sales Channels
8.7.1 Peripherally Acting Anti-Obesity Drug Sales Model
8.7.2 Peripherally Acting Anti-Obesity Drug Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Peripherally Acting Anti-Obesity Drug Introduction
1.2 World Peripherally Acting Anti-Obesity Drug Supply & Forecast
1.2.1 World Peripherally Acting Anti-Obesity Drug Production Value (2018 & 2022 & 2029)
1.2.2 World Peripherally Acting Anti-Obesity Drug Production (2018-2029)
1.2.3 World Peripherally Acting Anti-Obesity Drug Pricing Trends (2018-2029)
1.3 World Peripherally Acting Anti-Obesity Drug Production by Region (Based on Production Site)
1.3.1 World Peripherally Acting Anti-Obesity Drug Production Value by Region (2018-2029)
1.3.2 World Peripherally Acting Anti-Obesity Drug Production by Region (2018-2029)
1.3.3 World Peripherally Acting Anti-Obesity Drug Average Price by Region (2018-2029)
1.3.4 North America Peripherally Acting Anti-Obesity Drug Production (2018-2029)
1.3.5 Europe Peripherally Acting Anti-Obesity Drug Production (2018-2029)
1.3.6 China Peripherally Acting Anti-Obesity Drug Production (2018-2029)
1.3.7 Japan Peripherally Acting Anti-Obesity Drug Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Peripherally Acting Anti-Obesity Drug Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Peripherally Acting Anti-Obesity Drug Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Peripherally Acting Anti-Obesity Drug Demand (2018-2029)
2.2 World Peripherally Acting Anti-Obesity Drug Consumption by Region
2.2.1 World Peripherally Acting Anti-Obesity Drug Consumption by Region (2018-2023)
2.2.2 World Peripherally Acting Anti-Obesity Drug Consumption Forecast by Region (2024-2029)
2.3 United States Peripherally Acting Anti-Obesity Drug Consumption (2018-2029)
2.4 China Peripherally Acting Anti-Obesity Drug Consumption (2018-2029)
2.5 Europe Peripherally Acting Anti-Obesity Drug Consumption (2018-2029)
2.6 Japan Peripherally Acting Anti-Obesity Drug Consumption (2018-2029)
2.7 South Korea Peripherally Acting Anti-Obesity Drug Consumption (2018-2029)
2.8 ASEAN Peripherally Acting Anti-Obesity Drug Consumption (2018-2029)
2.9 India Peripherally Acting Anti-Obesity Drug Consumption (2018-2029)
3 WORLD PERIPHERALLY ACTING ANTI-OBESITY DRUG MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Peripherally Acting Anti-Obesity Drug Production Value by Manufacturer (2018-2023)
3.2 World Peripherally Acting Anti-Obesity Drug Production by Manufacturer (2018-2023)
3.3 World Peripherally Acting Anti-Obesity Drug Average Price by Manufacturer (2018-2023)
3.4 Peripherally Acting Anti-Obesity Drug Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Peripherally Acting Anti-Obesity Drug Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Peripherally Acting Anti-Obesity Drug in 2022
3.5.3 Global Concentration Ratios (CR8) for Peripherally Acting Anti-Obesity Drug in 2022
3.6 Peripherally Acting Anti-Obesity Drug Market: Overall Company Footprint Analysis
3.6.1 Peripherally Acting Anti-Obesity Drug Market: Region Footprint
3.6.2 Peripherally Acting Anti-Obesity Drug Market: Company Product Type Footprint
3.6.3 Peripherally Acting Anti-Obesity Drug Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Peripherally Acting Anti-Obesity Drug Production Value Comparison
4.1.1 United States VS China: Peripherally Acting Anti-Obesity Drug Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: Peripherally Acting Anti-Obesity Drug Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: Peripherally Acting Anti-Obesity Drug Production Comparison
4.2.1 United States VS China: Peripherally Acting Anti-Obesity Drug Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Peripherally Acting Anti-Obesity Drug Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: Peripherally Acting Anti-Obesity Drug Consumption Comparison
4.3.1 United States VS China: Peripherally Acting Anti-Obesity Drug Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: Peripherally Acting Anti-Obesity Drug Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based Peripherally Acting Anti-Obesity Drug Manufacturers and Market Share, 2018-2023
4.4.1 United States Based Peripherally Acting Anti-Obesity Drug Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Peripherally Acting Anti-Obesity Drug Production Value (2018-2023)
4.4.3 United States Based Manufacturers Peripherally Acting Anti-Obesity Drug Production (2018-2023)
4.5 China Based Peripherally Acting Anti-Obesity Drug Manufacturers and Market Share
4.5.1 China Based Peripherally Acting Anti-Obesity Drug Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Peripherally Acting Anti-Obesity Drug Production Value (2018-2023)
4.5.3 China Based Manufacturers Peripherally Acting Anti-Obesity Drug Production (2018-2023)
4.6 Rest of World Based Peripherally Acting Anti-Obesity Drug Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based Peripherally Acting Anti-Obesity Drug Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Peripherally Acting Anti-Obesity Drug Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers Peripherally Acting Anti-Obesity Drug Production (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Peripherally Acting Anti-Obesity Drug Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Prescription Drugs
5.2.2 Non-prescription Drugs
5.3 Market Segment by Type
5.3.1 World Peripherally Acting Anti-Obesity Drug Production by Type (2018-2029)
5.3.2 World Peripherally Acting Anti-Obesity Drug Production Value by Type (2018-2029)
5.3.3 World Peripherally Acting Anti-Obesity Drug Average Price by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Peripherally Acting Anti-Obesity Drug Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hospital Pharmacies
6.2.2 Retail Pharmacies
6.2.3 Online Pharmacies
6.3 Market Segment by Application
6.3.1 World Peripherally Acting Anti-Obesity Drug Production by Application (2018-2029)
6.3.2 World Peripherally Acting Anti-Obesity Drug Production Value by Application (2018-2029)
6.3.3 World Peripherally Acting Anti-Obesity Drug Average Price by Application (2018-2029)
7 COMPANY PROFILES
7.1 Novo Nordisk A/S
7.1.1 Novo Nordisk A/S Details
7.1.2 Novo Nordisk A/S Major Business
7.1.3 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Product and Services
7.1.4 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 Novo Nordisk A/S Recent Developments/Updates
7.1.6 Novo Nordisk A/S Competitive Strengths & Weaknesses
7.2 Pfizer Inc.
7.2.1 Pfizer Inc. Details
7.2.2 Pfizer Inc. Major Business
7.2.3 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Product and Services
7.2.4 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 Pfizer Inc. Recent Developments/Updates
7.2.6 Pfizer Inc. Competitive Strengths & Weaknesses
7.3 Boehringer Ingelheim International GmbH
7.3.1 Boehringer Ingelheim International GmbH Details
7.3.2 Boehringer Ingelheim International GmbH Major Business
7.3.3 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Product and Services
7.3.4 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 Boehringer Ingelheim International GmbH Recent Developments/Updates
7.3.6 Boehringer Ingelheim International GmbH Competitive Strengths & Weaknesses
7.4 KVK Tech Inc.
7.4.1 KVK Tech Inc. Details
7.4.2 KVK Tech Inc. Major Business
7.4.3 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Product and Services
7.4.4 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.4.5 KVK Tech Inc. Recent Developments/Updates
7.4.6 KVK Tech Inc. Competitive Strengths & Weaknesses
7.5 Gelesis Holdings
7.5.1 Gelesis Holdings Details
7.5.2 Gelesis Holdings Major Business
7.5.3 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Product and Services
7.5.4 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.5.5 Gelesis Holdings Recent Developments/Updates
7.5.6 Gelesis Holdings Competitive Strengths & Weaknesses
7.6 Vivus LLC.
7.6.1 Vivus LLC. Details
7.6.2 Vivus LLC. Major Business
7.6.3 Vivus LLC. Peripherally Acting Anti-Obesity Drug Product and Services
7.6.4 Vivus LLC. Peripherally Acting Anti-Obesity Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.6.5 Vivus LLC. Recent Developments/Updates
7.6.6 Vivus LLC. Competitive Strengths & Weaknesses
7.7 Currax Pharmaceuticals LLC
7.7.1 Currax Pharmaceuticals LLC Details
7.7.2 Currax Pharmaceuticals LLC Major Business
7.7.3 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Product and Services
7.7.4 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.7.5 Currax Pharmaceuticals LLC Recent Developments/Updates
7.7.6 Currax Pharmaceuticals LLC Competitive Strengths & Weaknesses
7.8 GlaxoSmithKline plc
7.8.1 GlaxoSmithKline plc Details
7.8.2 GlaxoSmithKline plc Major Business
7.8.3 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Product and Services
7.8.4 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.8.5 GlaxoSmithKline plc Recent Developments/Updates
7.8.6 GlaxoSmithKline plc Competitive Strengths & Weaknesses
7.9 CHEPLAPHARM Arzneimittel GmbH
7.9.1 CHEPLAPHARM Arzneimittel GmbH Details
7.9.2 CHEPLAPHARM Arzneimittel GmbH Major Business
7.9.3 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Product and Services
7.9.4 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.9.5 CHEPLAPHARM Arzneimittel GmbH Recent Developments/Updates
7.9.6 CHEPLAPHARM Arzneimittel GmbH Competitive Strengths & Weaknesses
7.10 Rhythm Pharmaceuticals
7.10.1 Rhythm Pharmaceuticals Details
7.10.2 Rhythm Pharmaceuticals Major Business
7.10.3 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Product and Services
7.10.4 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.10.5 Rhythm Pharmaceuticals Recent Developments/Updates
7.10.6 Rhythm Pharmaceuticals Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Peripherally Acting Anti-Obesity Drug Industry Chain
8.2 Peripherally Acting Anti-Obesity Drug Upstream Analysis
8.2.1 Peripherally Acting Anti-Obesity Drug Core Raw Materials
8.2.2 Main Manufacturers of Peripherally Acting Anti-Obesity Drug Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Peripherally Acting Anti-Obesity Drug Production Mode
8.6 Peripherally Acting Anti-Obesity Drug Procurement Model
8.7 Peripherally Acting Anti-Obesity Drug Industry Sales Model and Sales Channels
8.7.1 Peripherally Acting Anti-Obesity Drug Sales Model
8.7.2 Peripherally Acting Anti-Obesity Drug Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Peripherally Acting Anti-Obesity Drug Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World Peripherally Acting Anti-Obesity Drug Production Value by Region (2018-2023) & (USD Million)
Table 3. World Peripherally Acting Anti-Obesity Drug Production Value by Region (2024-2029) & (USD Million)
Table 4. World Peripherally Acting Anti-Obesity Drug Production Value Market Share by Region (2018-2023)
Table 5. World Peripherally Acting Anti-Obesity Drug Production Value Market Share by Region (2024-2029)
Table 6. World Peripherally Acting Anti-Obesity Drug Production by Region (2018-2023) & (K Units)
Table 7. World Peripherally Acting Anti-Obesity Drug Production by Region (2024-2029) & (K Units)
Table 8. World Peripherally Acting Anti-Obesity Drug Production Market Share by Region (2018-2023)
Table 9. World Peripherally Acting Anti-Obesity Drug Production Market Share by Region (2024-2029)
Table 10. World Peripherally Acting Anti-Obesity Drug Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World Peripherally Acting Anti-Obesity Drug Average Price by Region (2024-2029) & (US$/Unit)
Table 12. Peripherally Acting Anti-Obesity Drug Major Market Trends
Table 13. World Peripherally Acting Anti-Obesity Drug Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World Peripherally Acting Anti-Obesity Drug Consumption by Region (2018-2023) & (K Units)
Table 15. World Peripherally Acting Anti-Obesity Drug Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World Peripherally Acting Anti-Obesity Drug Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key Peripherally Acting Anti-Obesity Drug Producers in 2022
Table 18. World Peripherally Acting Anti-Obesity Drug Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key Peripherally Acting Anti-Obesity Drug Producers in 2022
Table 20. World Peripherally Acting Anti-Obesity Drug Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global Peripherally Acting Anti-Obesity Drug Company Evaluation Quadrant
Table 22. World Peripherally Acting Anti-Obesity Drug Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and Peripherally Acting Anti-Obesity Drug Production Site of Key Manufacturer
Table 24. Peripherally Acting Anti-Obesity Drug Market: Company Product Type Footprint
Table 25. Peripherally Acting Anti-Obesity Drug Market: Company Product Application Footprint
Table 26. Peripherally Acting Anti-Obesity Drug Competitive Factors
Table 27. Peripherally Acting Anti-Obesity Drug New Entrant and Capacity Expansion Plans
Table 28. Peripherally Acting Anti-Obesity Drug Mergers & Acquisitions Activity
Table 29. United States VS China Peripherally Acting Anti-Obesity Drug Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China Peripherally Acting Anti-Obesity Drug Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China Peripherally Acting Anti-Obesity Drug Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based Peripherally Acting Anti-Obesity Drug Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Peripherally Acting Anti-Obesity Drug Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers Peripherally Acting Anti-Obesity Drug Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers Peripherally Acting Anti-Obesity Drug Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers Peripherally Acting Anti-Obesity Drug Production Market Share (2018-2023)
Table 37. China Based Peripherally Acting Anti-Obesity Drug Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Peripherally Acting Anti-Obesity Drug Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers Peripherally Acting Anti-Obesity Drug Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers Peripherally Acting Anti-Obesity Drug Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers Peripherally Acting Anti-Obesity Drug Production Market Share (2018-2023)
Table 42. Rest of World Based Peripherally Acting Anti-Obesity Drug Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Peripherally Acting Anti-Obesity Drug Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers Peripherally Acting Anti-Obesity Drug Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers Peripherally Acting Anti-Obesity Drug Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers Peripherally Acting Anti-Obesity Drug Production Market Share (2018-2023)
Table 47. World Peripherally Acting Anti-Obesity Drug Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World Peripherally Acting Anti-Obesity Drug Production by Type (2018-2023) & (K Units)
Table 49. World Peripherally Acting Anti-Obesity Drug Production by Type (2024-2029) & (K Units)
Table 50. World Peripherally Acting Anti-Obesity Drug Production Value by Type (2018-2023) & (USD Million)
Table 51. World Peripherally Acting Anti-Obesity Drug Production Value by Type (2024-2029) & (USD Million)
Table 52. World Peripherally Acting Anti-Obesity Drug Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World Peripherally Acting Anti-Obesity Drug Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World Peripherally Acting Anti-Obesity Drug Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World Peripherally Acting Anti-Obesity Drug Production by Application (2018-2023) & (K Units)
Table 56. World Peripherally Acting Anti-Obesity Drug Production by Application (2024-2029) & (K Units)
Table 57. World Peripherally Acting Anti-Obesity Drug Production Value by Application (2018-2023) & (USD Million)
Table 58. World Peripherally Acting Anti-Obesity Drug Production Value by Application (2024-2029) & (USD Million)
Table 59. World Peripherally Acting Anti-Obesity Drug Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World Peripherally Acting Anti-Obesity Drug Average Price by Application (2024-2029) & (US$/Unit)
Table 61. Novo Nordisk A/S Basic Information, Manufacturing Base and Competitors
Table 62. Novo Nordisk A/S Major Business
Table 63. Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Product and Services
Table 64. Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. Novo Nordisk A/S Recent Developments/Updates
Table 66. Novo Nordisk A/S Competitive Strengths & Weaknesses
Table 67. Pfizer Inc. Basic Information, Manufacturing Base and Competitors
Table 68. Pfizer Inc. Major Business
Table 69. Pfizer Inc. Peripherally Acting Anti-Obesity Drug Product and Services
Table 70. Pfizer Inc. Peripherally Acting Anti-Obesity Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. Pfizer Inc. Recent Developments/Updates
Table 72. Pfizer Inc. Competitive Strengths & Weaknesses
Table 73. Boehringer Ingelheim International GmbH Basic Information, Manufacturing Base and Competitors
Table 74. Boehringer Ingelheim International GmbH Major Business
Table 75. Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Product and Services
Table 76. Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Boehringer Ingelheim International GmbH Recent Developments/Updates
Table 78. Boehringer Ingelheim International GmbH Competitive Strengths & Weaknesses
Table 79. KVK Tech Inc. Basic Information, Manufacturing Base and Competitors
Table 80. KVK Tech Inc. Major Business
Table 81. KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Product and Services
Table 82. KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 83. KVK Tech Inc. Recent Developments/Updates
Table 84. KVK Tech Inc. Competitive Strengths & Weaknesses
Table 85. Gelesis Holdings Basic Information, Manufacturing Base and Competitors
Table 86. Gelesis Holdings Major Business
Table 87. Gelesis Holdings Peripherally Acting Anti-Obesity Drug Product and Services
Table 88. Gelesis Holdings Peripherally Acting Anti-Obesity Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Gelesis Holdings Recent Developments/Updates
Table 90. Gelesis Holdings Competitive Strengths & Weaknesses
Table 91. Vivus LLC. Basic Information, Manufacturing Base and Competitors
Table 92. Vivus LLC. Major Business
Table 93. Vivus LLC. Peripherally Acting Anti-Obesity Drug Product and Services
Table 94. Vivus LLC. Peripherally Acting Anti-Obesity Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 95. Vivus LLC. Recent Developments/Updates
Table 96. Vivus LLC. Competitive Strengths & Weaknesses
Table 97. Currax Pharmaceuticals LLC Basic Information, Manufacturing Base and Competitors
Table 98. Currax Pharmaceuticals LLC Major Business
Table 99. Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Product and Services
Table 100. Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 101. Currax Pharmaceuticals LLC Recent Developments/Updates
Table 102. Currax Pharmaceuticals LLC Competitive Strengths & Weaknesses
Table 103. GlaxoSmithKline plc Basic Information, Manufacturing Base and Competitors
Table 104. GlaxoSmithKline plc Major Business
Table 105. GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Product and Services
Table 106. GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 107. GlaxoSmithKline plc Recent Developments/Updates
Table 108. GlaxoSmithKline plc Competitive Strengths & Weaknesses
Table 109. CHEPLAPHARM Arzneimittel GmbH Basic Information, Manufacturing Base and Competitors
Table 110. CHEPLAPHARM Arzneimittel GmbH Major Business
Table 111. CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Product and Services
Table 112. CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 113. CHEPLAPHARM Arzneimittel GmbH Recent Developments/Updates
Table 114. Rhythm Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 115. Rhythm Pharmaceuticals Major Business
Table 116. Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Product and Services
Table 117. Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 118. Global Key Players of Peripherally Acting Anti-Obesity Drug Upstream (Raw Materials)
Table 119. Peripherally Acting Anti-Obesity Drug Typical Customers
Table 120. Peripherally Acting Anti-Obesity Drug Typical Distributors
Table 1. World Peripherally Acting Anti-Obesity Drug Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World Peripherally Acting Anti-Obesity Drug Production Value by Region (2018-2023) & (USD Million)
Table 3. World Peripherally Acting Anti-Obesity Drug Production Value by Region (2024-2029) & (USD Million)
Table 4. World Peripherally Acting Anti-Obesity Drug Production Value Market Share by Region (2018-2023)
Table 5. World Peripherally Acting Anti-Obesity Drug Production Value Market Share by Region (2024-2029)
Table 6. World Peripherally Acting Anti-Obesity Drug Production by Region (2018-2023) & (K Units)
Table 7. World Peripherally Acting Anti-Obesity Drug Production by Region (2024-2029) & (K Units)
Table 8. World Peripherally Acting Anti-Obesity Drug Production Market Share by Region (2018-2023)
Table 9. World Peripherally Acting Anti-Obesity Drug Production Market Share by Region (2024-2029)
Table 10. World Peripherally Acting Anti-Obesity Drug Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World Peripherally Acting Anti-Obesity Drug Average Price by Region (2024-2029) & (US$/Unit)
Table 12. Peripherally Acting Anti-Obesity Drug Major Market Trends
Table 13. World Peripherally Acting Anti-Obesity Drug Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World Peripherally Acting Anti-Obesity Drug Consumption by Region (2018-2023) & (K Units)
Table 15. World Peripherally Acting Anti-Obesity Drug Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World Peripherally Acting Anti-Obesity Drug Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key Peripherally Acting Anti-Obesity Drug Producers in 2022
Table 18. World Peripherally Acting Anti-Obesity Drug Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key Peripherally Acting Anti-Obesity Drug Producers in 2022
Table 20. World Peripherally Acting Anti-Obesity Drug Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global Peripherally Acting Anti-Obesity Drug Company Evaluation Quadrant
Table 22. World Peripherally Acting Anti-Obesity Drug Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and Peripherally Acting Anti-Obesity Drug Production Site of Key Manufacturer
Table 24. Peripherally Acting Anti-Obesity Drug Market: Company Product Type Footprint
Table 25. Peripherally Acting Anti-Obesity Drug Market: Company Product Application Footprint
Table 26. Peripherally Acting Anti-Obesity Drug Competitive Factors
Table 27. Peripherally Acting Anti-Obesity Drug New Entrant and Capacity Expansion Plans
Table 28. Peripherally Acting Anti-Obesity Drug Mergers & Acquisitions Activity
Table 29. United States VS China Peripherally Acting Anti-Obesity Drug Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China Peripherally Acting Anti-Obesity Drug Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China Peripherally Acting Anti-Obesity Drug Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based Peripherally Acting Anti-Obesity Drug Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Peripherally Acting Anti-Obesity Drug Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers Peripherally Acting Anti-Obesity Drug Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers Peripherally Acting Anti-Obesity Drug Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers Peripherally Acting Anti-Obesity Drug Production Market Share (2018-2023)
Table 37. China Based Peripherally Acting Anti-Obesity Drug Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Peripherally Acting Anti-Obesity Drug Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers Peripherally Acting Anti-Obesity Drug Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers Peripherally Acting Anti-Obesity Drug Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers Peripherally Acting Anti-Obesity Drug Production Market Share (2018-2023)
Table 42. Rest of World Based Peripherally Acting Anti-Obesity Drug Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Peripherally Acting Anti-Obesity Drug Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers Peripherally Acting Anti-Obesity Drug Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers Peripherally Acting Anti-Obesity Drug Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers Peripherally Acting Anti-Obesity Drug Production Market Share (2018-2023)
Table 47. World Peripherally Acting Anti-Obesity Drug Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World Peripherally Acting Anti-Obesity Drug Production by Type (2018-2023) & (K Units)
Table 49. World Peripherally Acting Anti-Obesity Drug Production by Type (2024-2029) & (K Units)
Table 50. World Peripherally Acting Anti-Obesity Drug Production Value by Type (2018-2023) & (USD Million)
Table 51. World Peripherally Acting Anti-Obesity Drug Production Value by Type (2024-2029) & (USD Million)
Table 52. World Peripherally Acting Anti-Obesity Drug Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World Peripherally Acting Anti-Obesity Drug Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World Peripherally Acting Anti-Obesity Drug Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World Peripherally Acting Anti-Obesity Drug Production by Application (2018-2023) & (K Units)
Table 56. World Peripherally Acting Anti-Obesity Drug Production by Application (2024-2029) & (K Units)
Table 57. World Peripherally Acting Anti-Obesity Drug Production Value by Application (2018-2023) & (USD Million)
Table 58. World Peripherally Acting Anti-Obesity Drug Production Value by Application (2024-2029) & (USD Million)
Table 59. World Peripherally Acting Anti-Obesity Drug Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World Peripherally Acting Anti-Obesity Drug Average Price by Application (2024-2029) & (US$/Unit)
Table 61. Novo Nordisk A/S Basic Information, Manufacturing Base and Competitors
Table 62. Novo Nordisk A/S Major Business
Table 63. Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Product and Services
Table 64. Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. Novo Nordisk A/S Recent Developments/Updates
Table 66. Novo Nordisk A/S Competitive Strengths & Weaknesses
Table 67. Pfizer Inc. Basic Information, Manufacturing Base and Competitors
Table 68. Pfizer Inc. Major Business
Table 69. Pfizer Inc. Peripherally Acting Anti-Obesity Drug Product and Services
Table 70. Pfizer Inc. Peripherally Acting Anti-Obesity Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. Pfizer Inc. Recent Developments/Updates
Table 72. Pfizer Inc. Competitive Strengths & Weaknesses
Table 73. Boehringer Ingelheim International GmbH Basic Information, Manufacturing Base and Competitors
Table 74. Boehringer Ingelheim International GmbH Major Business
Table 75. Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Product and Services
Table 76. Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Boehringer Ingelheim International GmbH Recent Developments/Updates
Table 78. Boehringer Ingelheim International GmbH Competitive Strengths & Weaknesses
Table 79. KVK Tech Inc. Basic Information, Manufacturing Base and Competitors
Table 80. KVK Tech Inc. Major Business
Table 81. KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Product and Services
Table 82. KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 83. KVK Tech Inc. Recent Developments/Updates
Table 84. KVK Tech Inc. Competitive Strengths & Weaknesses
Table 85. Gelesis Holdings Basic Information, Manufacturing Base and Competitors
Table 86. Gelesis Holdings Major Business
Table 87. Gelesis Holdings Peripherally Acting Anti-Obesity Drug Product and Services
Table 88. Gelesis Holdings Peripherally Acting Anti-Obesity Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Gelesis Holdings Recent Developments/Updates
Table 90. Gelesis Holdings Competitive Strengths & Weaknesses
Table 91. Vivus LLC. Basic Information, Manufacturing Base and Competitors
Table 92. Vivus LLC. Major Business
Table 93. Vivus LLC. Peripherally Acting Anti-Obesity Drug Product and Services
Table 94. Vivus LLC. Peripherally Acting Anti-Obesity Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 95. Vivus LLC. Recent Developments/Updates
Table 96. Vivus LLC. Competitive Strengths & Weaknesses
Table 97. Currax Pharmaceuticals LLC Basic Information, Manufacturing Base and Competitors
Table 98. Currax Pharmaceuticals LLC Major Business
Table 99. Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Product and Services
Table 100. Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 101. Currax Pharmaceuticals LLC Recent Developments/Updates
Table 102. Currax Pharmaceuticals LLC Competitive Strengths & Weaknesses
Table 103. GlaxoSmithKline plc Basic Information, Manufacturing Base and Competitors
Table 104. GlaxoSmithKline plc Major Business
Table 105. GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Product and Services
Table 106. GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 107. GlaxoSmithKline plc Recent Developments/Updates
Table 108. GlaxoSmithKline plc Competitive Strengths & Weaknesses
Table 109. CHEPLAPHARM Arzneimittel GmbH Basic Information, Manufacturing Base and Competitors
Table 110. CHEPLAPHARM Arzneimittel GmbH Major Business
Table 111. CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Product and Services
Table 112. CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 113. CHEPLAPHARM Arzneimittel GmbH Recent Developments/Updates
Table 114. Rhythm Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 115. Rhythm Pharmaceuticals Major Business
Table 116. Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Product and Services
Table 117. Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 118. Global Key Players of Peripherally Acting Anti-Obesity Drug Upstream (Raw Materials)
Table 119. Peripherally Acting Anti-Obesity Drug Typical Customers
Table 120. Peripherally Acting Anti-Obesity Drug Typical Distributors
LIST OF FIGURES
Figure 1. Peripherally Acting Anti-Obesity Drug Picture
Figure 2. World Peripherally Acting Anti-Obesity Drug Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Peripherally Acting Anti-Obesity Drug Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World Peripherally Acting Anti-Obesity Drug Production (2018-2029) & (K Units)
Figure 5. World Peripherally Acting Anti-Obesity Drug Average Price (2018-2029) & (US$/Unit)
Figure 6. World Peripherally Acting Anti-Obesity Drug Production Value Market Share by Region (2018-2029)
Figure 7. World Peripherally Acting Anti-Obesity Drug Production Market Share by Region (2018-2029)
Figure 8. North America Peripherally Acting Anti-Obesity Drug Production (2018-2029) & (K Units)
Figure 9. Europe Peripherally Acting Anti-Obesity Drug Production (2018-2029) & (K Units)
Figure 10. China Peripherally Acting Anti-Obesity Drug Production (2018-2029) & (K Units)
Figure 11. Japan Peripherally Acting Anti-Obesity Drug Production (2018-2029) & (K Units)
Figure 12. Peripherally Acting Anti-Obesity Drug Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Peripherally Acting Anti-Obesity Drug Consumption (2018-2029) & (K Units)
Figure 15. World Peripherally Acting Anti-Obesity Drug Consumption Market Share by Region (2018-2029)
Figure 16. United States Peripherally Acting Anti-Obesity Drug Consumption (2018-2029) & (K Units)
Figure 17. China Peripherally Acting Anti-Obesity Drug Consumption (2018-2029) & (K Units)
Figure 18. Europe Peripherally Acting Anti-Obesity Drug Consumption (2018-2029) & (K Units)
Figure 19. Japan Peripherally Acting Anti-Obesity Drug Consumption (2018-2029) & (K Units)
Figure 20. South Korea Peripherally Acting Anti-Obesity Drug Consumption (2018-2029) & (K Units)
Figure 21. ASEAN Peripherally Acting Anti-Obesity Drug Consumption (2018-2029) & (K Units)
Figure 22. India Peripherally Acting Anti-Obesity Drug Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of Peripherally Acting Anti-Obesity Drug by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for Peripherally Acting Anti-Obesity Drug Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for Peripherally Acting Anti-Obesity Drug Markets in 2022
Figure 26. United States VS China: Peripherally Acting Anti-Obesity Drug Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: Peripherally Acting Anti-Obesity Drug Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Peripherally Acting Anti-Obesity Drug Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers Peripherally Acting Anti-Obesity Drug Production Market Share 2022
Figure 30. China Based Manufacturers Peripherally Acting Anti-Obesity Drug Production Market Share 2022
Figure 31. Rest of World Based Manufacturers Peripherally Acting Anti-Obesity Drug Production Market Share 2022
Figure 32. World Peripherally Acting Anti-Obesity Drug Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World Peripherally Acting Anti-Obesity Drug Production Value Market Share by Type in 2022
Figure 34. Prescription Drugs
Figure 35. Non-prescription Drugs
Figure 36. World Peripherally Acting Anti-Obesity Drug Production Market Share by Type (2018-2029)
Figure 37. World Peripherally Acting Anti-Obesity Drug Production Value Market Share by Type (2018-2029)
Figure 38. World Peripherally Acting Anti-Obesity Drug Average Price by Type (2018-2029) & (US$/Unit)
Figure 39. World Peripherally Acting Anti-Obesity Drug Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 40. World Peripherally Acting Anti-Obesity Drug Production Value Market Share by Application in 2022
Figure 41. Hospital Pharmacies
Figure 42. Retail Pharmacies
Figure 43. Online Pharmacies
Figure 44. World Peripherally Acting Anti-Obesity Drug Production Market Share by Application (2018-2029)
Figure 45. World Peripherally Acting Anti-Obesity Drug Production Value Market Share by Application (2018-2029)
Figure 46. World Peripherally Acting Anti-Obesity Drug Average Price by Application (2018-2029) & (US$/Unit)
Figure 47. Peripherally Acting Anti-Obesity Drug Industry Chain
Figure 48. Peripherally Acting Anti-Obesity Drug Procurement Model
Figure 49. Peripherally Acting Anti-Obesity Drug Sales Model
Figure 50. Peripherally Acting Anti-Obesity Drug Sales Channels, Direct Sales, and Distribution
Figure 51. Methodology
Figure 52. Research Process and Data Source
Figure 1. Peripherally Acting Anti-Obesity Drug Picture
Figure 2. World Peripherally Acting Anti-Obesity Drug Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Peripherally Acting Anti-Obesity Drug Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World Peripherally Acting Anti-Obesity Drug Production (2018-2029) & (K Units)
Figure 5. World Peripherally Acting Anti-Obesity Drug Average Price (2018-2029) & (US$/Unit)
Figure 6. World Peripherally Acting Anti-Obesity Drug Production Value Market Share by Region (2018-2029)
Figure 7. World Peripherally Acting Anti-Obesity Drug Production Market Share by Region (2018-2029)
Figure 8. North America Peripherally Acting Anti-Obesity Drug Production (2018-2029) & (K Units)
Figure 9. Europe Peripherally Acting Anti-Obesity Drug Production (2018-2029) & (K Units)
Figure 10. China Peripherally Acting Anti-Obesity Drug Production (2018-2029) & (K Units)
Figure 11. Japan Peripherally Acting Anti-Obesity Drug Production (2018-2029) & (K Units)
Figure 12. Peripherally Acting Anti-Obesity Drug Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Peripherally Acting Anti-Obesity Drug Consumption (2018-2029) & (K Units)
Figure 15. World Peripherally Acting Anti-Obesity Drug Consumption Market Share by Region (2018-2029)
Figure 16. United States Peripherally Acting Anti-Obesity Drug Consumption (2018-2029) & (K Units)
Figure 17. China Peripherally Acting Anti-Obesity Drug Consumption (2018-2029) & (K Units)
Figure 18. Europe Peripherally Acting Anti-Obesity Drug Consumption (2018-2029) & (K Units)
Figure 19. Japan Peripherally Acting Anti-Obesity Drug Consumption (2018-2029) & (K Units)
Figure 20. South Korea Peripherally Acting Anti-Obesity Drug Consumption (2018-2029) & (K Units)
Figure 21. ASEAN Peripherally Acting Anti-Obesity Drug Consumption (2018-2029) & (K Units)
Figure 22. India Peripherally Acting Anti-Obesity Drug Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of Peripherally Acting Anti-Obesity Drug by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for Peripherally Acting Anti-Obesity Drug Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for Peripherally Acting Anti-Obesity Drug Markets in 2022
Figure 26. United States VS China: Peripherally Acting Anti-Obesity Drug Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: Peripherally Acting Anti-Obesity Drug Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Peripherally Acting Anti-Obesity Drug Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers Peripherally Acting Anti-Obesity Drug Production Market Share 2022
Figure 30. China Based Manufacturers Peripherally Acting Anti-Obesity Drug Production Market Share 2022
Figure 31. Rest of World Based Manufacturers Peripherally Acting Anti-Obesity Drug Production Market Share 2022
Figure 32. World Peripherally Acting Anti-Obesity Drug Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World Peripherally Acting Anti-Obesity Drug Production Value Market Share by Type in 2022
Figure 34. Prescription Drugs
Figure 35. Non-prescription Drugs
Figure 36. World Peripherally Acting Anti-Obesity Drug Production Market Share by Type (2018-2029)
Figure 37. World Peripherally Acting Anti-Obesity Drug Production Value Market Share by Type (2018-2029)
Figure 38. World Peripherally Acting Anti-Obesity Drug Average Price by Type (2018-2029) & (US$/Unit)
Figure 39. World Peripherally Acting Anti-Obesity Drug Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 40. World Peripherally Acting Anti-Obesity Drug Production Value Market Share by Application in 2022
Figure 41. Hospital Pharmacies
Figure 42. Retail Pharmacies
Figure 43. Online Pharmacies
Figure 44. World Peripherally Acting Anti-Obesity Drug Production Market Share by Application (2018-2029)
Figure 45. World Peripherally Acting Anti-Obesity Drug Production Value Market Share by Application (2018-2029)
Figure 46. World Peripherally Acting Anti-Obesity Drug Average Price by Application (2018-2029) & (US$/Unit)
Figure 47. Peripherally Acting Anti-Obesity Drug Industry Chain
Figure 48. Peripherally Acting Anti-Obesity Drug Procurement Model
Figure 49. Peripherally Acting Anti-Obesity Drug Sales Model
Figure 50. Peripherally Acting Anti-Obesity Drug Sales Channels, Direct Sales, and Distribution
Figure 51. Methodology
Figure 52. Research Process and Data Source
